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Abstract
Background:  Linking population health data to pathology data is a new approach for the
evaluation of predictive tests that is potentially more efficient, feasible and efficacious than current
methods. Studies evaluating the use of first trimester maternal serum levels as predictors of
complications in pregnancy have mostly relied on resource intensive methods such as prospective
data collection or retrospective chart review. The aim of this pilot study is to demonstrate that
record-linkage between a pathology database and routinely collected population health data sets
provides follow-up on patient outcomes that is as effective as more traditional and resource-
intensive methods. As a specific example, we evaluate maternal serum levels of PAPP-A and free
β-hCG as predictors of adverse pregnancy outcomes, and compare our results with those of
prospective studies.
Methods: Maternal serum levels of PAPP-A and free β-hCG for 1882 women randomly selected
from a pathology database in New South Wales (NSW) were linked to routinely collected birth
and hospital databases. Crude relative risks were calculated to investigate the association between
low levels (multiples of the median ≤ 5th percentile) of PAPP-A or free β-hCG and the outcomes
of preterm delivery (<37 weeks), small for gestational age (<10th percentile), fetal loss and stillbirth.
Results: Using only full name, sex and date of birth for record linkage, pregnancy outcomes were
available for 1681 (89.3%) of women included in the study. Low levels of PAPP-A had a stronger
association with adverse pregnancy outcomes than a low level of free β-hCG which is consistent
with results in published studies. The relative risk of having a preterm birth with a low maternal
serum PAPP-A level was 3.44 (95% CI 1.96–6.10) and a low free β-hCG level was 1.31 (95% CI
0.55–6.16).
Conclusion:  This study provides data to support the use of record linkage for outcome
ascertainment in studies evaluating predictive tests. Linkage proportions are likely to increase if
more personal identifiers are available. This method of follow-up is a cost-efficient technique and
can now be applied to a larger cohort of women.
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Background
Routinely collected data or population-health datasets
(PHDS) have been used to address key issues in health.
The population coverage and accessibility make PHDS an
attractive and cost effective resource for research allowing
description of the total burden of disease in the popula-
tion, assessment of risk factors and casual pathways[1]
and investigation of rare outcomes[2]. Linkage of popula-
tion health data to pathology data is a new approach for
evaluating predictive tests that is potentially more effi-
cient and efficacious than current methods. Traditional
methods for evaluation of predictive tests require evalua-
tion in a representative spectrum of patients, and com-
plete follow-up.[3] Such studies are often performed
prospectively and require considerable resources. Success-
ful linkage of pathology databases with those that rou-
tinely report health outcomes could provide a powerful
and important tool for the evaluation of the clinical use-
fulness of a range of newly discovered biomarkers.
In Australia, antenatal screening for fetal anomalies, such
as Down syndrome, has occurred since the 1980s[4,5].
The current screening test for Down syndrome combines
first trimester maternal serum levels of pregnancy-associ-
ated plasma protein-A (PAPP-A) and free beta-human
chorionic gonadotropin (free β-hCG) with ultrasound
fetal nuchal translucency (NT) measurements and mater-
nal age. An English study estimated that the detection rate
with this type of screening is almost 90%[6].
There has been interest in the use of first trimester mater-
nal serum biomarkers to predict other adverse pregnancy
outcomes. Low levels of PAPP-A have been found to be
associated with fetal growth restriction or low birth weight
[7-14], preterm delivery[7-11,15] and fetal loss or still-
birth[7,9,12,15]. Studies investigating free β-hCG and
adverse pregnancy outcomes have had mixed
results[7,8,11,16].
The aim of this pilot study is to demonstrate that record-
linkage between a pathology database and routinely col-
lected population health data sets provides follow-up on
patient outcomes that is as effective as more traditional
and resource-intensive methods. As a specific example, we
evaluate maternal serum levels of PAPP-A and free β-hCG
as predictors of adverse pregnancy outcomes, and com-
pare our results with those of previous studies.
Methods
The dataset used in this analysis was built by linking
records from three separate sources. The Pacific Labora-
tory Medicine Services (PaLMs) is a business unit of a net-
work of northern Sydney public hospitals and analyses
serum samples collected from across New South Wales
(NSW), including both metropolitan Sydney and regional
areas. The Midwives' Data Collection (MDC) is a legis-
lated surveillance system of all births in NSW, reported by
the attending midwife or doctor. The Admitted Patient
Data Collection (APDC) has records of all hospital dis-
charges in NSW (public and private), up to 55 diagnosis
fields for each admission coded according to the 10th
revision of the International Classification of Diseases –
Australian Modification (ICD10-AM). Hospital records
are available for liveborn infants, as well for mothers'
antenatal and delivery admissions. MDC and APDC
records were available for deliveries and hospital dis-
charges up to 31 December 2006.
The initial study sample was randomly selected from
blood tests collected for first trimester Down syndrome
screening and analysed at the PaLMs laboratory, with the
exclusion of known twin gestations. Both PAPP-A and free
β-hCG were reported for each pregnancy. The initial sam-
ple included 2000 randomly selected tests collected
between 1 January and 30 June 2006, subsequently
reduced to 1882 women who were expected to deliver
before 31 December 2006.
The record linkage for the study was conducted by an
independent body (the NSW Centre for Health Record
Linkage [CHeReL: http://www.cherel.org.au]), in accord-
ance with NSW privacy guidelines and subject to ethics
approval. Because there are no unique patient identifiers
in use in the NSW health care system, probabilistic match-
ing of personal identifiers (such as full name, date of
birth, sex, address, hospital code and hospital record
number) is used for linkage. Probabilistic record linkage
involves the calculation of linkage probability weights,
adjusting for data entry errors, incomplete and missing
data, and has been described in detail elsewhere.[17,18]
Once linked, personal identifiers are removed and a
unique project person ID number is assigned to each
record. Based on this linkage, data custodians of the rele-
vant datasets provide health data (no identifiers) to
researchers ensuring researchers at no time have access to
identifying personal information and the risk to personal
privacy is minimised.
For this pilot study, only mother's full name, sex and date
of birth were available for linking laboratory records to
pregnancy outcome data in the MDC and APDC. For preg-
nancies where multiple matches were possible (i.e. com-
mon names), no definite link to an outcome record could
be established. This study was approved by the NSW Pop-
ulation and Health Services Research Ethics Committee.
PAPP-A and free β-hCG measurement
Samples collected from regional centres were frozen prior
to transport. An Immulite 2000 immuno-analyser (Sie-
mens Healthcare Diagnostics) was used to measure serumBMC Medical Research Methodology 2009, 9:48 http://www.biomedcentral.com/1471-2288/9/48
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levels of PAPP-A and free β-hCG. Both PAPP-A and free β-
hCG results are reported as multiples of the median
(MoM) corrected for gestational age and maternal weight,
where provided, at sample collection. Corrections are
based on the distributions of PAPP-A and free β-hCG in
the laboratory's obstetric population. Gestational age was
usually estimated by ultrasound, but date of last men-
strual period was used where an ultrasound estimate was
not recorded. For comparison with results from other
studies, a cut-off of ≤ 5 th percentile MoM was used to
define low PAPP-A and low free β-hCG results. This has
been the most commonly used threshold in previous
studies of these biomarkers as predictors of prematurity
and intrauterine growth restriction.
Pregnancy outcomes
Outcomes were selected that could be compared with pre-
viously published studies. The primary outcomes were
preterm birth (birth at 24–36 weeks gestation) and small-
for-gestational-age (SGA). SGA births were categorised as
<10th birthweight percentile for gestational age, by sex,
using Australian standard birthweight percentiles[19].
Secondary outcomes were fetal loss (death before 24
weeks) and stillbirth (death in utero at ≥ 24 weeks). A com-
posite outcome comprising fetal loss, stillbirth, birth at ≤
37 weeks gestation or SGA birth was also analysed,
although this was not directly comparable to results from
other studies.
Statistical analysis
The t test for unpaired samples was used to test for differ-
ences between linked and unlinked pregnancies for mean
values of maternal factors or blood test results. A chi-
square test was used to test for difference in proportions.
McNemar's test was used to test for a difference in sensi-
tivity for low PAPP-A versus low free β-hCG in the linked
pregnancies. Sensitivity was defined as the percentage of
pregnancies that resulted in an adverse outcome which
were flagged as "at risk" by a PAPP-A or free β-hCG result
≤ 5 th  percentile. Positive predictive value (PPV) was
defined as the percentage of pregnancies that had an
adverse outcome out of all pregnancies which tested "pos-
itive" for risk (had a PAPP-A or free β-hCG result ≤ 5th per-
centile). The associations between low values of PAPP-A
and free β-hCG and the pregnancy outcomes are pre-
sented as crude risk ratios (RR) with 95% confidence
intervals (95% CI).
Results
Of the 1882 women who had an expected delivery date in
2006, linkage to a pregnancy outcome record was estab-
lished for 1681 (89.3%), leaving 201 (10.7%) with no
outcome data. A further 16 twin pregnancies, 11 medical
terminations less than 20 weeks gestation and 4 infants
diagnosed with aneuploidies were excluded, so that 1650
pregnancies were included in the analysis. The median
gestational age at which samples were collected was 12+1
weeks, with a range of 10+0 to 13+6 weeks. Table 1 shows a
comparison of days gestation at sample collection, mater-
nal weight, PAPP-A and free β-hCG values, for the 1650
pregnancies in the analysis and the 201 pregnancies with
no outcome data. There was no evidence that the
unlinked pregnancies were different in regards to their
PAPP-A and free β-hCG results. For instance, P = 0.28 for
the test of a difference in proportion falling below the ≤
5th percentile PAPP-A cutoff (Table 1)
Seventeen of the 1650 pregnancies ended in a fetal loss at
<24 weeks, the remaining 1633 pregnancies linked to a
delivery record at ≥ 24 weeks gestation. Sixteen infants
were stillborn, with a gestational age range from 24 to 41
weeks. Among the 1617 livebirths, two (0.1%) were at
<28 weeks, 16 (1.0%) at 28–33 weeks, 52 (3.2%) at 34–
36 weeks and 1547 (95.7%) at ≥ 37 weeks.
The relative risks of adverse outcomes for pregnancies
with a PAPP-A MoM ≤ 5 th percentile and a free β-hCG
MoM ≤ 5th percentile are shown in Table 2. In this study
Table 1: Maternal factors and biomarker results for pregnancies that did and did not link to a pregnancy outcome record
Maternal factor at time of screen test Pregnancies linked to an outcome
N = 1650*
Unlinked pregnancies
N = 201
Test of difference
mean (sd) mean (sd)
Days gestation 84.9 (6.0) 85.7 (5.9) P = 0.08
Age (years) 32.6 (4.7) 32.0 (4.8) P = 0.13
Weight (kg) 67.1 (14.4)† 65.2 (14.4)† P = 0.13
PAPP-A (MoM) 1.19 (0.75) 1.24 (0.80) P = 0.49
free β-hCG (MoM) 1.24 (0.81) 1.18 (0.74) P = 0.26
≤ 5th percentile cutoff (%) ≤ 5thpercentile cutoff (%)
PAPP-A (MoM) 5.3 3.5 P = 0.28
free β-hCG (MoM) 5.2 5.0 P = 0.92
* multiple gestations, aneuploidies and pregnancies resulting in medical abortions excluded
† (records with missing weight: linked n = 299, unlinked n = 51)BMC Medical Research Methodology 2009, 9:48 http://www.biomedcentral.com/1471-2288/9/48
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population, the 5th percentile MoM values were 0.38 of
the median for PAPP-A and 0.40 of the median for free β-
hCG. PAPP-A had a stronger association with all four
adverse outcomes than free β-hCG. This was most evident
for preterm birth, where a low PAPP-A result had RR =
3.44 (95% CI 1.94, 6.10) while free β-hCG did not have a
statistically significant association.
The stronger association of PAPP-A with adverse out-
comes was also reflected in their respective sensitivities for
those outcomes, although the differences in sensitivity
were not statistically significant. For preterm birth, PAPP-
A had a sensitivity of 15.4% versus 6.4% for free β-hCG (P
= 0.14); for SGA birth, PAPP-A had a sensitivity of 9.9%
versus 9.2% for free β-hCG (P = 0.99). The positive predic-
tive value (PPV) of PAPP-A for preterm birth was 14.6%
and for free β-hCG was 6.2% (P = 0.08). For the compos-
ite outcome including preterm birth, fetal loss, stillbirth
and SGA birth, PAPP-A had a PPV of 31.0% and free β-
hCG had a PPV of 25.3% (P = 0.27).
Discussion
This study demonstrates the feasibility of using record-
linkage of a pathology database with existing population
health datasets to ascertain pregnancy outcomes for eval-
uating predictive tests. We found that a low level of PAPP-
A has a stronger association to adverse pregnancy out-
comes than a low level of free β-hCG which is consistent
with previous studies[7-10,20-22]. This study provides
data to support the use of such a cost-efficient technique
which can now be applied to assessment of other poten-
tial pregnancy screening factors (such as levels of the
VEGF family of proteins and their receptors in first trimes-
ter serum samples) in a larger cohort of women.
Prospective studies evaluating the diagnostic value of first
trimester maternal serum levels have shown a range of risk
estimates between low levels of PAPP-A or free β-hCG and
adverse pregnancy outcomes, as summarised in Tables 3A
and 3B. Although the results of our study show a stronger
association between PAPP-A and preterm delivery or fetal
loss than some of the larger published studies, the 95%
confidence intervals of all results overlap. Our study sam-
ple size (initially 2000 lab records, ultimately 1,650
women) was selected on the basis of being large enough
to show consistency with results published in other stud-
ies, not to demonstrate a clinical benefit of using these
particular maternal biochemical markers as predictors of
adverse outcomes in pregnancy. High levels of free β-hCG
in the second trimester have been associated with preterm
delivery[23] and fetal death[24] however in this study we
have focused on the predictive value of low levels of bio-
chemical markers in the first trimester.
Sensitivities and predictive values reported in previous
studies are also comparable to our results. Of those stud-
ies that used PAPP-A cut-offs less than the 5th percentile,
sensitivities for small for gestational age infants ranged
Table 2: PAPP-A and free β-hCG results and pregnancy outcomes
Pregnancy outcome PAPP-A ≤ 5th percentile (MoM = 0.38) free β-hCG ≤ 5th percentile (MoM = 0.41)
n/N RR (95% CI)* n/N RR (95% CI)*
Gestational age
Preterm birth 24–36 weeks† 12/78 3.44
(1.94, 6.10)
5/78 1.31
(0.55, 3.16)
Birth at ≥ 37 weeks† 70/1555 1.0 (referent) 76/1555 1.0 (referent)
Mortality outcome
Fetal loss <24 weeks 5/17 7.41
(2.67, 20.6)
4/17 5.61
(1.87, 16.8)
Stillbirth ≥ 24 weeks 0/16 not calculated 0/16 not calculated
Livebirth 82/1617 1.0 (referent) 81/1617 1.0 (referent)
Birthweight for gestational age
SGA† (<10th percentile) 13/131 2.08
(1.23, 3.53)
12/131 1.93
(1.11, 3.34)
≥ 10th percentile 69/1499 1.0 (referent) 69/1499 1.0 (referent)
Composite outcome
Fetal loss, stillbirth, birth <37 wks or SGA†† 27/228 2.41
(1.72, 3.39)
20/228 1.77
(1.18, 2.65)
Livebirth ≥ 10th percentile 60/1422 1.0 (referent) 65/1422 1.0 (referent)
* relative risk of respective pregnancy outcome given a PAPP-A or free β-hCG ≤ 5th percentile
† small for gestational age, includes stillbirths
†† small for gestational ageBMC Medical Research Methodology 2009, 9:48 http://www.biomedcentral.com/1471-2288/9/48
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from 7.8%[8] to 11.4%[22] compared to our result of
9.9% and positive predictive values ranged from
14.1%[10] to 16.7%[22] compared to our PPV of 15.8%.
For preterm birth, the sensitivity for PAPP-A lower than
the 5th percentile estimated from our results (15.5%) is
higher than reported in other studies (7.8% to 8.5%)[8,9]
however Kwik and Morris[14] demonstrated a sensitivity
of 17.7% for a PAPP-A cut-off at less than 0.5 MoM.
Rigorous evaluation of predictive serum tests traditionally
requires the assay to be performed in a prospective cohort,
representative of those in whom the test will be used in
clinical practice. In addition, patients and carers are
blinded to the test result and complete follow-up to the
endpoint of interest is required.[3] The follow-up of
women to ascertain pregnancy outcomes is often
obtained by interview with the study participants or
review of medical records. Outcomes derived from inter-
view are subject to patient recall bias[25,26] and possibly
to interviewer bias (if exposure is not blinded). Follow-up
of pregnant women is also difficult as a high proportion
of them are likely to have moved house during their preg-
nancy (around 20%)[27] and this non-response bias
would affect the validity and generalisability of the result.
Medical record review is time consuming, and both meth-
ods of follow-up are expensive. Ascertainment of preg-
nancy outcomes by linkage to existing population health
databases can overcome some of these constraints, the
costs of linkage in this study was AUD8500. In contrast,
the largest prospective study in pregnancy http://
www.scopestudy.net/news.aspx has been recruiting inter-
nationally for over 4 years and by April 2009 had enrolled
over 4000 women. This study involves repeated collection
of biological samples (including serum) during preg-
nancy and, to date has had AUD11.4M of funds allocated
with the aim of recruiting 10,000 women.
Table 3: Summary of results from this study and relevant published studies of PAPP-A and adverse pregnancy outcomes and Free β-
hCG and adverse pregnancy outcomes
A. PAPP-A and adverse pregnancy outcomes
Outcome PAPP-A Study Population (N) MoM cut-off OR/RR (95% CI)*
Preterm delivery <37 weeks This study 1,650 ≤ 5th percentile (0.38 MoM) 3.44 (1.94–6.10)
Barrett et al 2008[7] 10,273 ≤ 0.3 MoM 2.9 (2.0–4.2)
Smith et al 2002[11] 8,839 ≤ 5th percentile (0.40 MoM) 2.34 (1.75–3.12)
Dugoff et al 2004[9] 34,271 ≤ 5th percentile (0.42 MoM) 1.73 (1.47–2.04)†
Ong et al 2000[8] 5,297 ≤ 5th percentile 1.52 (0.91–2.55)
Birth weight ≤ 10th percentile for gestational age This study 1,650 ≤ 5th percentile (0.38 MoM) 2.08 (1.23–3.53)
Krantz et al 2004[10] 8,012 ≤ 5th percentile (0.45 MoM) 2.7 (1.9–3.9)††
Tul et al 2003[13] 1,136 ≤ 0.5 MoM 2.51 (1.30–4.83)
Dugoff et al 2004[9] 34,271 ≤ 5th percentile (0.42 MoM) 2.47 (2.16–2.81)†
Ong et al 2000[8] 5,297 ≤ 5th percentile 1.53 (1.08–2.17)
Fetal loss <24 weeks This study 1,650 ≤ 5th percentile (0.38 MoM) 7.41 (2.67–20.6)
Spencer et al 2006[21] 54,722 ≤ 5th percentile (0.42 MoM) 3.25
Dugoff et al 2004[9] 34,271 ≤ 5th percentile (0.42 MoM) 2.5 (1.76–3.56)†
B. Free β-hCG and adverse pregnancy outcomes
Outcome Free β-hCG Study Population (N) MoM cut-off OR/RR (95% CI)*
Preterm delivery <37 weeks This study 1,650 ≤ 5th percentile (0.41 MoM) 1.31 (0.55–3.16)
Barrett et al 2008[7] 10,273 ≤ 0.3 MoM 2.0 (1.3–3.1)
Ong et al 2000[8] 5,297 ≤ 5th percentile 1.29 (0.71–2.34)
Birth weight ≤ 10th percentile for gestational age This study 1,650 ≤ 5th percentile (0.41 MoM) 1.93 (1.11–3.34)
Ong et al 2000[8] 5,297 ≤ 5th percentile 1.38 (0.93–2.03)
Krantz et al 2004[10] 8,012 ≤ 5th percentile (0.45 MoM) 1.3 (0.8–2.0)††
Fetal loss <24 weeks This study 1,650 ≤ 5th percentile (0.41 MoM) 5.61 (1.87–16.8)
Spencer et al 2006[21] 54,722 ≤ 5th percentile (0.41 MoM) 3.1
*The crude relative risk and 95% confidence intervals has been calculated from published results where possible
†OR adjusted for maternal age, maternal weight, parity, previous preterm pregnancy, threatened abortion, smoking, use of antihypertensive drugs
††OR adjusted for maternal age, maternal weight, smoking, ethnicityBMC Medical Research Methodology 2009, 9:48 http://www.biomedcentral.com/1471-2288/9/48
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Using record linkage to attain outcome data can reduce
the risk to personal privacy for participants in research
studies[28]. In our study, the processes of record linkage
and data analysis were separated: use of identifiable data
was restricted to the record linkage, the linkage was con-
ducted by someone not involved in the research, and
access only to anonymised data were available to the
investigators, maximising protection of participants' pri-
vacy. Women participating in the study did not need to be
contacted again minimising the risk of harm to partici-
pants, especially those that have experienced a negative
outcome such as a fetal loss or infant death. A further
advantage is that the linkage to outcomes is done while
blinded to exposure, in this instance the laboratory
results.
In this study almost 90% of women could be linked to
pregnancy outcome data. This linkage rate is less than in
other studies[7], however linkage was only performed on
three identifying fields. A Scottish study using probabilis-
tic linkage of maternal surname, first and second initial,
date of birth and postcode, where available, reported a
linkage rate of 81%[29]. With more identifiers available
the linkage rate in this study should be improved consid-
erably. Using matching variables including full name,
address (including phonetic coding), postcode, country of
birth, hospital code and medical record number results in
over 98% of records linked[30].
The use of PHDS to determine pregnancy outcomes has its
limitations. Only outcomes that are routinely collected
can be evaluated and the quality of results is dependent
on the accuracy and completeness of data recorded in the
population datasets. Validation studies that compare
PHDS with corresponding medical records have shown
the outcomes used in this study to be reported reliably in
PHDS. The hospital data reporting of preterm birth has a
sensitivity of 76% [31] and in the MDC reporting of ges-
tational age has 85% exact agreement with medical
records[32]. Identifying outcomes from more than one
dataset, such as from both the MDC and the APDC, has
been shown to improve case ascertainment.[33] The time-
liness of the availability of routinely collected data may be
a limitation. Population data are collected all year and
then typically closed out at the end of the financial or cal-
endar year. The data must then be cleaned before linkage
can be done; in total this process can take a number of
years. Despite these limitations data linkage is a powerful
method to investigate possible associations that may be
worth pursuing.
Conclusion
This feasibility study demonstrates that predictive tests
can be evaluated by linking pathology databases with rou-
tinely collected population health databases that report
pregnancy outcomes. This method of outcome ascertain-
ment is less expensive than other methods of follow-up,
minimises potential biases associated with outcome col-
lection and loss to follow up and reduces the risk to
patient privacy. Record linkage will provide a powerful
and important tool for the evaluation of the clinical use-
fulness of a range of newly discovered biomarkers with
major implications for translating research findings into
clinical practice, not only in pregnancy and newborn
health but also longer term health outcomes.
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